| 0.2875 -0.033 (-10.16%) | 12-07 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.48 | 1-year : | 0.6 |
| Resists | First : | 0.41 | Second : | 0.51 |
| Pivot price | 0.35 |
|||
| Supports | First : | 0.25 | Second : | 0.21 |
| MAs | MA(5) : | 0.33 |
MA(20) : | 0.34 |
| MA(100) : | 0.38 |
MA(250) : | 1.64 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 9.4 |
D(3) : | 21.6 |
| RSI | RSI(14): 41.8 |
|||
| 52-week | High : | 9.52 | Low : | 0.2 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ JAGX ] has closed above bottom band by 4.3%. Bollinger Bands are 3.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.32 - 0.32 | 0.32 - 0.32 |
| Low: | 0.28 - 0.28 | 0.28 - 0.29 |
| Close: | 0.28 - 0.29 | 0.29 - 0.29 |
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer for multiple possible follow-on indications, including cancer therapy-related diarrhea; orphan-drug indications for symptomatic relief of diarrhea in infants and children with congenital diarrheal disorders and for adult and pediatric patients for short bowel syndrome with intestinal failure with; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops lechlemer, a second-generation anti-secretory agent for cholera; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. Jaguar Health, Inc. was founded in 2013 and is headquartered in San Francisco, California.
Thu, 07 Dec 2023
MASCC (Multinational Association of Supportive Care in Cancer) Webinar on GI Toxicities from Cancer Therapies ... - Yahoo Finance
Wed, 06 Dec 2023
Study Data on Quality of Life for Breast Cancer Patients and Survivors, Supported by Napo Pharmaceuticals (a Jaguar ... - Yahoo Finance
Mon, 04 Dec 2023
FDA renews conditional approval for Jaguar canine chemo drug (JAGX) - Seeking Alpha
Mon, 04 Dec 2023
FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea in Dogs - Yahoo Finance
Tue, 21 Nov 2023
Jaguar Health’s stock drops after results supporting ‘paramount’ trial have not been received yet - MarketWatch
Fri, 17 Nov 2023
Jaguar Health Third Quarter 2023 Earnings: Beats Expectations - Simply Wall St
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 51 (M) |
| Held by Insiders | 4.554e+007 (%) |
| Held by Institutions | 17.6 (%) |
| Shares Short | 905 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.101e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -312.4 % |
| Return on Assets (ttm) | -42.8 % |
| Return on Equity (ttm) | -1 % |
| Qtrly Rev. Growth | 1.072e+007 % |
| Gross Profit (p.s.) | -6.23 |
| Sales Per Share | 365.16 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -0.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -32 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 9.89 |
| Dividend | 0 |
| Forward Dividend | 827870 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|